Docket #: S17-285
A clinical test for early diagnosis of abdominal aortic aneurysm
Stanford inventors have developed an early-stage screening method to diagnose abdominal aortic aneurysms (AAA). AAA is a common cardiovascular disease with high prevalence in European men 65 years and above. Even though there is a mortality rate of 90%, the current method of diagnosis is often by accidental ultrasound, and usually at very late stages.
Despite a strong genetic component, understanding of AAA is still limited, so there is no effective screening test for AAA in early stages. This invention, as a product from our scientific research, aims to fill this gap and provide an effective solution for early AAA diagnosis and screening.
Stage of Development:
Applications
- Clinical Screening for AAA
Advantages
- Genetic-based screening for AAA, allowing for earlier diagnosis.
- Enables effective healthcare practices; targeted approach can pinpoint vulnerable groups of people rather than broad screens
Publications
- Li J, Pan C, Zhang S, Spin JM, Deng A, Leung LLK, Dalman RL, Tsao PS, Snyder M. Decoding the Genomics of Abdominal Aortic Aneurysm. Cell. 2018 Sep 6;174(6):1361-1372.e10.
Related Links
Patents
- Published Application: WO2019139950
- Published Application: 20210158894
Similar Technologies
-
NeuMapper: a scalable computational framework for modeling brain dynamics S21-295NeuMapper: a scalable computational framework for modeling brain dynamics
-
Breast Cancer Detection using an engineered B7-H3 affibody ligand S17-486Breast Cancer Detection using an engineered B7-H3 affibody ligand
-
Precision Immunotherapy: AI-Powered Biomarkers for Predicting Outcomes in Advanced Esophagogastric Cancer S24-099Precision Immunotherapy: AI-Powered Biomarkers for Predicting Outcomes in Advanced Esophagogastric Cancer